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Special Report

A BRAVE NEW WORLD

The Influence of Biotechnology on Society,
Its Health, and the Environment
Transcripts from a Symposium Sponsored by the Minnesota Academy of Sciences
April 28, 1984
Conveners and Editors
Thomas Molitor
College of Veterinary Medicine,
University of Minnesota, St. Paul
Dennis Anderson
Molecular Genetics, Inc., Minnetonka

Editor's Note: On April 28, 1984, a special symposium was held during the 52nd Annual Spring Meeting of the
Minnesota Academy of Sciences. In an attempt to serve the best interests of both the academic research community
and the general public, this symposium was conceived as a means of shedding light on the recent publicity and
controversies surrounding the application of the "high tech " discipline called biotechnology. Recent advances in
biology, particularly mo lecular biology, have spawned a "new science" called biotechnology. In reality, biotechno logy encompasses a collection of long-established sciences, that are now augmented by a greater understanding of
biochemical and genetic processes at the mol ecular leveL With the advent of recombinant DNA, a new era in biol ogy
was ushered in whereby knowledge gained from basic research could now be applied in a practical manner to benefit
humankind. Indeed, biotechnology has been heralded as the ultimate answer to man's problems, as well as the
ultimate eviL In reality, biotechnology is neither of these things; it is merely a collection of techniques or tools which
were developed to further our understanding of ourselves and the world around us.
In an effort to understand both the technical and human nature of this "new" science, this symposium brought
together two recognized and respected experts in the field of biotechnology: Lynn W. Enquist, former Director of
Research and Development at Molecular Genetics, Inc., and V. Elving Anderson, Director of the Dight Institute for
Genetic Research at the University of Minnesota, Minneapolis. The abridged text of Dr. Enquist's and Dr. Anderson 's
talks are presented on the following pages.

The Impact of Biotechnology on
Human and Animal Health
Lynn W. Enquist

Lynn Enquist received his doctorate in microbiology from
the Medical College of Virginia, Richmond, in 1971. From
1971 through 1973, he served as a postdoctoral fellow in the
Department of Cell Biology, Roche Institute of Molecular Biology. Dr. Enquist held the positions of staff fellow and then
scientist with the Laboratory of Molecular Genetics (NICHD)
of the National Institutes of Health from 1973 to 1977, and
was associated with the virus tumor biology section within the
Laboratory of Molecular Virology at the National Cancer
Institute -NIH from 1977through 1981 .1n 1981, he became
Research Director of Animal Health and Plant Products with
Molecular Genetics, Inc. He has since taken a position with E.!
Dupont de Nemours, Research and Development Laboratories
in Wilmington, Delaware.
Dr. Enquist's research interests are focused on the rearran4

gement ofgenetic information in prokaryotes and eukaryotic
viruses. He is especially concerned with mechanisms of DNA
synthesis and control processes active during replication and
recombination of bacteriophage Lambda and the expression
of foreign genes in Escherichia coli. As Research Director with
Molecular Genetics, In c., he maintained an active research
interest in the gene structure and Junction in Herpes viruses.
Herewith follows an abridged transcript of Dr. Enquist's
presentation:
Biotechnology is a novel, and often startling, technology
that is beginning to make an impact on humanity. I believe
very few of us realize the impact it is going to have on our own
personal lives over the next few years. It's not that these
innovati ons are very complicated. To the contrary, the problem really is that they are so simple. We are not newcomers to
technical innovation; we have seen several technological
revolutions that have changed the way we live. Obvious
examples are nuclear power and computers. The hectic pace
of our lives continues, and we now find ourselves in the midst
of another revolution of even greater magnitude than those
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we have experienced before. However, unlike previous tech
nological breakthroughs, we are in a position, unique in
mankind's history, to look ahead and see what is in store for us
while having a chance to direct the technology. The new
revolution is biotechnology, the manipulation of genes and
cells.
The first point to remember is that biotechnology really is a
technology: it originally represented only a tool that aided
research. Like other technologies, biotechnology can be
exploited for commercial purposes. Biotechnology, by my
definition, is any technique using living organisms or parts of
organisms to make or modify products, to improve plants or
animals, or to develop microorganisms or cells for specifi c
uses.
Biotechnology has been with us for a long time. From the
dawn of recorded history, examples exist where man has
exploited the living creatures around him. He uses microorganisms to improve food by fermentation and expl oits wild
animals and wild plants for domestication through breeding.
Such applications are examples of directed genetic engineering in a natural way. Biotechnology is no stranger to us at that
level.
But today's revolution in biotechnology is very different.
Man now has the ability to directly manipulate the hereditary
material (genes) of cells to create new fo rms of life. It is now
possible to take genes from one organism and transfer them
to an unrelated organism. Such gene transfer may result in
very interesting organisms, or more likely, may result in
nothing of value. Nevertheless, the important fact is that we
now have the ability to directly manipulate cells and genes.
The exciting and frighte ning issue for some people is that we
are learning to utilize biotechnology very quickly. Biotech nology is not a single discipline ; rather, it is a fusion of a
whole series of ideas and techniques from many areas of
study including biochemistry, molecular biology, genetics,
and physics. The explosion of knowledge in this field has
become apparent in the last seven years.
It was in 1840 that Frederick Miescher discovered nuclein,
an entity that was subsequently proven to be DNA, although
he did not know that at the time. It took some hundred years
( 1940) before Avery proved that DNA was the hereditary or
genetic material of life. In 1953, Warson and Crick deduced
th e structure of the DNA molecul e. In 1963,Jacob and Monad
established the principles by which bacteria regulate their
genes. At the same time, the genetic code of DNA was broken;
man could now "speak the language of genes. " In 1967,
enzymes which could che mically join DNA molecules (DNA
ligases) were discovered, and in 1970 it was discovered that
restriction e nzymes (which cut DNA at very specific sites or
locations in the mol ecule) actually had some value in laboratory research. The year 1973 was critical, for it was in this year
that it became obvious one could purify DNA from an organism, cut it at predetermined sites with absolute specificity via
restriction enzymes and then reconstruct the DNA correctly in
the test tube. This era of recombinant DNA or gene-splicing
technology had arrived. You can see that it took over a
hundred years to arrive at that point; however, from 1973 to
1983, the pace has been explosive.
In 1974, the first evidence of artificial gene transfer in
bacteria was obtained. Simultaneously, public awareness that
recombinant DNA might be something for concern was felt.
You have probably seen the magazine articles decrying
"tinkering with life." Scientists felt this social responsibility
and responded positive ly. In 1975, researchers, for the first
time in the history of scie nce, declared a public moratorium
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,) n resea1·ch (involving recombinant DNA). They established

nationally enforced research guidelines and promoted the
discussion and review of relevant reco mbinant DNA research.
The National Institutes of Health (NIH) guidelines for
recombinant DNA research are rather detailed and affect o nly
those doing research supported by the U.S. government. For
example, if you receive an NIH grant, you must agree that you
will foll ow the NIH guidelines. Although not required to do
so, priYate companies which do recombinant DNA research
abide, in principl e, to the rules; no responsible company
would go against the NIH guidelines.
In 1975 , another breakthrough occurred, the creation of
hybrido ma cells. These are special antibody-producing cells
formed by fusing two cell types together. A year later, the first
mammalian gene was isolated and observed in the electron
microscope, and its total DNA sequence established.
The first genetic engineering company was established in
1976 -- Genentech in San Francisco. In 1980, the Supreme
Court established that one could patent life forms -that is, if
one "engineered" a new bacterium in the laboratory, one
could patent it. The decision catalyzed new actiYity in the
commercial arena. Genentech stock went public in 1980 at an
initial price of$35. Within 20 minutes of trading, the price rose
to $89; the gold rush was o n! In 1981 , over 80 new companies
were established to commercialize recombinant DNA technology. The first fully automated gene synthesizer was made
in 1980 enabling one to make DNA by machine. Another
genetic engineering company made records on Wall Street in
1981 - Cetus, a California company, raised $125 million in aninitial public offering, the largest offering ever recorded. In
1982, the first recombinant DNA vaccine, Colibacillosis, was
developed in Europe. Insulin was produced in bacteria and
approved for use in the United States and Europe in 1982.
After 1983, the list of events becomes overwhelming. The
purpose of this litany of dates is to show that bi otechnology is
moving at an incredible pace -- so fast that even people in the
fiel d find it difficult to keep up with adYances. The general
public, therefore, needs to deal with the concern that they
may not be abl e to understand the basic issu es. The purpose
of symposia like this is to stress that even tho ugh progress is
very rapid, the technology is rather constant and what is
fueling progress is the application of this technology to more
and more problems. Scientists must counter fear with facts ;
consequently, I want to establish some principles about
biotechnology,
As I have indicated, biotechnology involves the restructuring and edi ting of geneti c information. In addition, it involves
restructuring of informati on to construct new microorganisms which can then be exploited to advance knowledge as
well as produce products of commercial value. What exactly
does restructuring and editing of DNA mean? Figure 1A is an
artist's conception of the do uble he lix structure of DNA. The
molecu le looks like a ladder in which the rungs contain the
elements of the genetic code and the outside supports hold
the molecule together. The rungs of the ladder are chemicals
called either purines or pyrimidin es. The name ofthe purines
are adenine and guanine and the names of the pyrimidines
are cytosine and thymine - A, G, T and C are the abbreviations. The combination of a purine or a pyrimidine and a
sugar and a phosphate is called a nucleotide. Using the ladder
analogy, the outside supports are the phosphates and the
sugars, and the inside rungs are the bases, A, T, G or C.
DNA has two strands. An A· from one strand always pairs
with T from the other; simi larly, G always pairs with C. The
strands are held together by such pairings through weak
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Figure 1. The structure and expression of genetic information.
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linkages called hydrogen bonds. The genetic code is formed
by the linear arrangement of the A, T, C and G nucleotides on
one strand of the DNA molecule. The code has a very simple
rule about genetic words: all words have only three letters. So
there are only 64 words in the genetic dictionary ( 4letters and
3 letters per word= 4 x 4 x 4 or 64 words). A surprising fact
about words in the genetic dictionary is that some words have
the same meaning; the code is redundant. A fundamental fact
of biology is that the genetic code is universal. There are no
examples of English, Chinese, Russian, or 'Japanese in the
language of life. All organisms have the same language based
on DNA. This explains why one can remove a piece of DNA
from one organism and place it into another one.
Although life looks fairly complex from an organismic
point of view, when examined at the molecular level, life is
fairly simplistic. Perhaps a simple concept to keep in mind is
that DNA molecules are something like recording tape.
Recording tape is linear, and the information is generally
encoded in a linear fashion. To read it, one must start at one
end and progress stepwise to the other. Splicing recording
tape is straightforward. One can remove the sixth word from a
particular statement, join the tape back together and have
something that may or may not make sense. The key point is
that one has now edited the tape. The same process can be
done with DNA. By keeping in mind the analogy of recording
tape, you will have a good working model of what a DNA
molecule acts like when it is inside the cell.
There are three key operational words that de fine how
information stored in DNA is used: replication, transcription,
and translation (Figure 1). In replication, DNA makes a copy
of itself by separating the two strands and copying each strand
(Figure lA). Because the strands are complementary, A always
pairs with T and G always pairs with C. Conceptually it is
simple to invoke an enzyme that can bring these nucleotides
together and line them up opposite another strand to make an
exact copy of the old strand. If this is done coordinately, two
copies can be made from one DNA molecule. Doing so copies
the genetic information. DNA, in principle, can be duplicated
so one copy would go to one daughter cell and one would go
to the other in the process of cell division.
The second key word is transcription: how the genetic
code gets read. The genetic code kept inside the DNA is not
where the "action is." The DNA is more or less like a hard disc
storage system on a computer; what is needed is a copy of the
information that can be sent out for use by the cell. In cells,
the strands of DNA open and a slightly different nucleic acid is
copied from one strand, thus providing a message or copy of
the code that is transported outside the nucleus and put to
work. This messenger molecule is called mRNA.
Translation, the third key word, is the reading of the code
contained in the mRNA copy. The mRNA, like recording tape,
must be passed over a reader in a linear fashi o n in order to
read the code (Figure lB). Remember that the code is read
three letters at a tim e. The reading element in cells is called a
ribosome. The mRNA binds to the ribosome and then ratchets
through the molecule, moving three bases at a time. Each
three-letter word, or "codon," specifies one amino acid;
amino acids are joined together in linear chains to make
proteins. The key molecule in reading the code is an "adaptor" molecule called transfer RNA (tRNA) . Each codon corresponds to a unique adaptor tRNA molecule that has three bases
complementary to each specific codon. Each tRNA carries one
specific amino acid to the riboso me. A$ each codon is read,
the corresponding amino acid is brought in and joined
together to make a protein.
journal of the Minnesota Academy of Science

In summary, in replication DNA is duplicated so that all the
progeny cells get copies of the genetic code. Transcription is
where the genetic code is copied into RNA and transferred to
the place where the code is read. Translation, or the reading
of the code, is the utilization of the information that results in
construction of proteins. The essence of life can be summarized by what is known as the central dogma: DNA makes
copies of itself and also makes RNA; RNA makes protein
(Figure lC).
With that as general background, let us consider what are
the major technologies that enabled biotechnology to assume
such a visible place, not only in research , but also in commerce and society. I have defined six techniques that I believe
represent some of the most important technologies involving
the manipulation of genes and cells.
Scientists have perfected the ability to isolate and produce
faithful copies of isolated genes in quantity and at will. By
knowing the genetic code and the common structural features of the DNA, general principles have been devised to
identify and purify DNA fragments containing genes of interest. The DNA sequences that encode the self-replication
machinery of certain viruses and small chromosomes have
been isolated and are used to replicate DNA fragments in
simple microorganisms of virtually any source. One can isolate a piece of DNA from organisms as diverse as mice, elephants, or plants; insert those DNA segments into selfreplicating DNA units; put the recombined DNA into bacteria
or yeast; and make many copies of the particular DNA segments. This is molecular cloning.
Second, scientists know how to splice genes. DNA is a
simple repeating p olymer that can be cut at specific places
and rejoined, as well as synthesized in the laboratory from
common chemicals. Molecular biologists can now take a gene
from one DNA molecule and chemically splice it to different
DNA molecule. This feat is called recombinant DNA techno!·
ogy because new gene combinations are made. The phrase
"genetic engineering" was coined to describe the microconstruction that occurs during gene splicing.
The third technique is gene transfer. Genes or DNA frag·
ments can be moved from test tube to living cell almost at will.
One such method is called micromanipulation. Many copies
of a gene are isolated and put into a very small glass pipette.
Using a microscope to guide the process, o ne can insert the
glass needle into the nucleus of a single cell and inject the
purified DNA directly into the nucleus. The new gene often
functions and replicates in its new environment. In another
technique, the DNA can be precipitated directly on cell
surfaces, and the cells take up the DNA much as they would
take up other objects they encounter. The DNA then makes its
way to the nucleus where it can function and be inherited for
generations.
The fourth technique is cell culture. It is possible to separate cells from an organism and grow them in a test tube.
Growing indi vidual cells in quantity for analysis has had an
enormous impact on biology. Recently this laboratory tool
has found its way into industry. It is now possible to grow
mammalian cells in large-scale fermenters much like bacteria,
which have been exploited by bioengineers for decades. It
was commonly perceived that only animal cells and microorganisms could grow in culture. However, over the past few
years, plant cells have become attractive for laboratory and
industrial exploitation. In addition, certain plant cells have a
novel property not available with animal cells. After growing
in culture, plant cells can be coaxed to give rise to whole
plants. This e nables a plant genetic engineer to manipulate
plant cells in the laboratory such that he or she can work with
Vo lume 50, Number 1, 1984/ 85

acres of potential plants in a few petri dishes.
The fifth technique is cell fusion . Using electric fields or
chemicals that melt cell surfaces, scientists can fuse two cell
types together to create a completely different hybrid cell.
Often these hybrids are unstable and die out, but occasionally
certain hybrids are stable and provide new forms of cells for
study and exploitation.
The sixth basic biotechnology technique involves embryo
transfer. Eggs from a variety of animals can be fertilized in the
test tube and the resulting embryos transferred to a suitable
mother where they develop normally. Since many of the other
biotechnology techniques listed above involve work with
DNA and manipulation of single cells, they can be directly
applied to these germ line cells as well. For example, a
fertilized egg with new DNA sequences can be transferred to a
foster mother; the offspring, which can be recovered, now
carries the new DNA sequences which were inserted into the
fertilized egg by microinjection or other methods. In this way
new gene combinations can be introduced into the whole
animal rather than into individual cells. Presently embryo
transfer is of great interest in veterinary medicine because it
enables one to take eggs from a valuable animal, fertilize
them in a test tube , and implant them in less valuable carrier
mothers. The prized animal thus bypasses the stress of
pregnancy.
Let us now consider a specific example of the application of
recombinant DNA technology to problems of interest to
science, medicine, or commerce: the construction of a bacterium synthesizing a protein to be used as a p otential Herpes
virus vaccine. Herpes simplex virus is a complex biological
agent. It has a lipid overcoat with viral proteins called glycoproteins studding the surface. Inside the overcoat is the virus
capsid, the proteins that cover the DNA molecule of the virus.
Inside the capsid is a large single DNA molecule of about
150,000 base pairs that encode about 100-200 genes. The
glycoproteins on the surface are of medical importance; if
your body encounters the virus for the first time, your
immune system responds to these surface glycoproteins by
making antibodies to the proteins that are on the surface of
the virus. These antibodies are capable of protecting you from
a Herpes virus infection.
What was done to make a recombinant DNA vaccine was to
isolate the genes that make those surface proteins. Each surface protein gene was then spliced into the DNA of a bacterium so that the viral protein could be made in large quantities. We can now make the glycoproteins in bacteria and inject
them into mice or guinea pigs to protect them from infection
by virulent Herpes simplex virus. The test of this potential
vaccine in people will probably be initiated early next year.
Another example of this capability involves transfer of the
human growth hormon e (HGH) gene into mice. This example actually brings out a basic ethical issue. Because most
people are not so much concerned about what can be done
with bacteria, but rather what can be done with humans, gene
transfer between humans and mice is striking. The experiment, done two years ago, involved transfer of the human
HGH gene into mice resulting in offspri ng twice the size of
their normal counterparts. The outcome raises many important qu estions. From the scientific point of view, the questions
of how all of this works are very exciting. From an ethical
point of view, one must consider if the experiment could o r
should be done in humans. Of course, one can do it in
humans, because there is nothing special about the technology. However, the issues of whether you would want to and
what the ramifications would be are serious questions yet to
be answered.
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Figure 2. The producti on of monoclonal antibodies.

Another example of the power of biotechnology is plant
tissue culture. This is an example of technology developed at
Molecular Genetics, Inc. Our scientists take immature
embryos fro m corn and transfer the m to petri dishes containing nutrients and a plant growth hormone. At first, the
embryos begin to grow in an undifferentiated manner; they
form into lumps of tissue called callus. The tissues grow that
way almost indefinitely as long as they are transferred to fresh
media containing the plant growth hormone. Such callus
cultures can be exposed to different environmental insu lts,
like herbicides or temperature extremes, and resistant cell
lines can be isolated and established. This technology brings
to the realm of plant sciences the ability to manipulate cells
with the ease and the facility reserved for microbiologists.
What is truly pheno menal, however, is that o ne can take these
clumps of cells, transfer the m to media without growth hormone, and regenerate healthy plants. Often these plants have
the characteristics of the parent plant, but occasio nally th ey
pick up new traits. If the cells were selected to be resistant to
an herbicide, for example, the plants regenerated from such
cells are typically herbicide resistant. Thus, o ne can manipulate plant cells in culture and create novel plants.
The final exampl e of this new technology is cell fusion , a
technique now being exploited to create products for both
human and veterinary marketplaces. In the mid 1970's, a cell
fusi o n technique was developed that gave antibodyproducing cells a kind of immortality (Figure 2). Basically,
antibody-producing cells are fused with certain lo ng-lived
cells called myelo ma cells. The antibody cell (which doesn 't
live very long, but makes the antibody you want) is fused to
the myeloma cells (which makes nothing that you are interested in, but lives forever) creating a new kind of cell called a
hybridoma. Each hybridoma cell must be isolated, cultured
into coloni es, and tested to see if it is making the desired
antibody.
Molecular Genetics, Inc. has used this cell fusion technique
to make our first product, Geneco)TM99, a monoclonal antibody. We wanted to make a pure antibody preparation that
8

inactivated a bacterium that causes severe diarrhea in newborn calves. We did this by first injecting the surface proteins
ofthis bacterium into mice from which hybridoma cells were
formed. The right hybrido ma cell producing therapeutic
antibody for this disease of newborn calves was found. The
antibodies were tested and shown to protect animals against
disease. We have scaled up this laboratory finding to commercial size and have, to o ur knowledge, the world's first
factory manufacturing kilogram quantities of antibody using
monoclonal technology.
The striking fact is that this technology was pioneered in
the late 1960's and was first used only in the laboratory. Only
recently have we realized that it had any commercial value. In
two years' time, our scientists identified a problem, designed
a product, built a factory and have product in a box. The point
is that biotechnology is really not something of the 21st
century, but something that is here and now. New products
and ideas will be coming o ut at an increasi ng pace, not o nly
for agriculture but also for human health care.
I will end with a summary of some current advances in
biotechnology. First and most obvio us are new products. I've
discussed some examples of gene products made by
microorganisms; others include Interferon , tissue plasminogen activator, protein kinases that dissolve blood clots, and
reagents that are going to be useful in diagnosing cancer.
Another advance is in gene analysis~ medical diagnosis at
the molecular level. Scientists now use the same systems for
isolati on and gene transfer to study single genes in a population and determine if a given gene is normal or mutant. I
discussed a particular example where the human growth
horm one gene was transferred to a mouse. Agromegaly, a
human growth hormo ne defect, is treated by giving external
growth hormones. One can now consider correcting this
defect by gen e transfer of a good human growth hormone
gene.
Rapid progress is being made in creating new p rocesses for
production of chemicals and drugs. There are many exampl es
of enzymatic activities present in certain organisms that are
journal of th e Minnesota Acad emy of Science

difficult to grow. One can now conceive of transferring the
desired genes to more commercially facile organisms. We can
expect much research and development in this area.
Advances in plant tissue culture will provide new plant
varieties. I discussed the example of corn, but for the past five
or so years there have been examples of potatoes and raspber·
ries being, propagated by tissue culture to be virus-free, for
example.
Biomass conversion is an area where research is active and
the benefits are great. A lot of waste from sugarcane, algae,
weeds, etc. is not used. This biomass contains potential fuel
and food . Scientists are designing new kinds of bacteria and
processes to obtain methane, heat, and products from plant
waste materials.
A major advance is occurring in instrumentation. I gave an
example of machines that are being used to synthesize DNA.
This represents only a small fraction of the machines now
available to biotechnologists. Whole fields of study are being
set up to use living cells as part of instruments. For example,
cells are very sensitive to chemical gradients. Bioprobes may
be constructed to measure chemicals and events within cells
with increased sensitivity.
Computer technology is expanding into biotechnology to
help scientists understand the molecular process in living
systems. New concepts are being developed which imply
using biological molecules as the working components of
computers - so-called "biochips. " Monoclonal antibodies
and proteins produced in bacteria could be used to build or
recognize different kinds of information, thus forming novel
storage and transfer devices. DNA, after all , is the ultimate
computer - it contains an enormous amount of information
stored in a very small volume. There are many modern-day
wizards thinking about ways to make computers based on the
same kind of techniques that DNA uses to process genetic
information inside the cell.
One final item essential to technology is imagination.
Experiments, products, and impossible techniques become
not only possible but practical. There are so many possibilities that it boggles the mind. I mentioned producing hormones by microbial fermentation. You can literally produce
thousands of pounds of hormones this way if you have the
right kind offermenter. These could be animal hormones that
improve fertility, milk production, or feed conversion. You
can insert genes for vaccine antigens or hormones into plants
using plant tissue culture technology so that people could eat
these plants and pick up vaccines or hormones through their
breakfast cereal. You can use plant tissue culture to select
plant variants resistant to insects, fungi, herbicides, industrial
pollutants, heavy metals, salt, cold, heat, or flooding. It is
possible to splice genes for antibodies into microbial factories; instead of making antisera by injecting antigens into
animals , you can make antisera by growing a little culture of
bacteria. You can consider animal breeding, not by conventional technology, but instead by gene transfer, cell culture,
cell fusion, and embryo transplants.
It's clear that these six technical innovations I have presented plus imagination are indeed the seeds of a revolution in
all biology. We have a chance to come to grips with a novel
technology as it's being developed. It is an exciting and
unique position to be in; the opportunities begin in the
molecular biology laboratories but provide equally challenging vistas for every aspect of commerce and for society that
thinks to capitalize on or be worried about this new revolution in science and our society.

•••••
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PUBLIC POLICY ISSUES
CONCERNING BIOTECHNOLOGY

V. Elving Anderson

V Elving Anderson received his doctorate from the University of Minnesota in 1953. He served at Bethel College in St.
Paul as chairman of the Biology Department from 1952
through 1960 and as acting dean from 1954 through 1965.
Dr. Anderson has been president of several academic socie·
ties, including the American Scientific Affiliation, Minnesota
Academy of Science, Academy Conference of AmericanAsso·
ciation for the Advancement of Science, the Institute for
Advanced Christian Studies, and the Behavior Genetics Association. Recently, Dr. Anderson has filled the position of President of Sigma Xi, the Scientific Research Society, and now
serves on the Boards of Bethel College and Seminary, as well as
the Institute for Advanced Christian Studies. He currently
holds the position of Professor of Genetics at the University of
Minnesota, Minneapolis.
Dr. Anderson's research interests concern genetic factors in
epilepsy, mental retardation, diabetes, psychotic disorders,
and other human behavioral problems. Herewith follows an
abridged transcript of Dr. Anderson's presentation:
Many people, when they think about biotechnology and
genetic engineering, have in mind a picture of Frankenstein
and his monster. The creature was unusually sensitive, but
was perceived by others as not human. Therefore, he was
rejected. Frankenstein's monster has become the symbol ,af
dangers in the misuse of technology.
There was another individual who was despised and cast
aside by society. That person, immortalized in the film Elephant Man, suffered from neurofibromatosis, a disfiguring
genetic disorder. The extent of the defect can be quite
variable, from scarcely noticeable to quite severe. The problem is whether we will be so frightened by the image of
Frankenstein's monster that we will be unable to deal with
genetic defects like the one experienced by the Elephant
Man.
One possible conceptual framework is presented in Table
1. In the left column are three functions of science, each with
an associated cluster of ethical problems. When people think
about biotechnology or genetic engineering, they often do
not realize that the greatest use of recombinant DNA methods
at the present time is at the level of understanding. Now,
understanding itself does bring some problems. If you find
out that you are a carrier of a harmful gene, it can affect your
decisions. For example, if you know you possess the gene for
Huntington disease, you realize that you are fated to have,
somewhere between the age of fifteen and fifty-five, the onset
of a progressive and untreatable neurological disorder.
The second level is prediction, with the associated ethical
problems of choice. Prenatal diagnosis, for example, sometimes leads to termination of a pregnancy. I should point out,
however that no more than about two percent of genetic
prenatal tests lead to termination. In fact, it is estimated that
more babies are born as the result of having such tests
available than are terminated by abortion, since families who
know they carry genetic defects would otherwise choose not
to have a child.
The third level was outlined by Dr. Enquist in his discussion of the possibilities for change and the ethical problems
that are involved.
One of the temptations in dealing with science and technology is to treat problems on too narrow a basis. In this
discussion, however, I am more concerned about unwar9

ranted expectations. A physician who writes a column for one
of our genetic journals told of a woman who stated firmly,
"Doctor, I do not want to have this baby unless it will be
perfect." There is no way that anyone can make that guarantee. It is unfortunate that growth in our understanding and
ability to predict sometimes can lead to the unjustifiable
conclusion that it is possible to avoid all undesirable
consequences.
Another temptation is the misuse of power. Both information and techniques for control do convey power. Part of our
concern here is to keep power as much as possible in the
hands of the individuals who are directly involved.
To end with these cautions is not enough, however. In
order to provide some positive statements, I have used the
familiar trilogy: faith, hope , and love. Recently I attended a
conference in Boston on genetics and the law. Albert]onsen,
an ethicist, told of his experiences in talking with famili es
who were considering fetal surgery. At present, there are two
conditions in which operations on the fetus are possible
- hydrocephalus and urinary tract defects. It is his impression
that informed consent for the procedure comes only after
faith in the doctors has been established. The mother or the
father of the unborn child face many uncertainties , but a
decision not to intervene also has its problems. That is why
]onsen described the present status of fetal surgery with the
phrase "adventures in faith ." At some level there has to be
faith in someone.
Hope is also needed. If we are not to be paralyzed by fear
we need a sense that things can be done correctly. Love also is
appropriate. Science and technology continually alter our
concept of what it means to be good neighbors. Table 1 forms
three sets of three; you can reorganize those terms in a
number of combinations that will be instructive.
Table 1. A conceptual fram ework for science and technology.
FUNCTIONS
OF SCIENCE
(ETHICS)

TEMPTATIONS

POSITIVE
QUALITIES

EXPLAIN
(Knowing)

NARROW
WORLDVIEW

FAITH

PREDICT
(Choosing)

UNWARRANTED
EXPECTATION

HOPE

CONTROL
(Changing)

MISUSE OF
POWER

LOVE

Now a few examples. The first will be the topic of recombinant DNA markers. Part of my own research is on a disorder
call ed cerebellar ataxia. Each child of an affected parent has a
50 percent chance of devel opi ng the condition. No one shows
the signs before age fifte en, but everyone who is going to get
it will do so by age thirty-five. Th e interval between onset and
death is seldom more than ten years. We have been studying a
large family located in Minn esota and South Dakota. Earli er
studies indicate that the gene for this disorder is on chromosome 6 near the genes for HlA. (HlA testing helps to determine whether or not a donor kidney will be accepted by a
recipient.) A group in Utah has identified some other markers
on chromosome 6 that are developed by using restricti on
enzymes to cut DNA. We are now getting new blood samples
for DNA analysis to see if we can define the locatio n of the
ataxia gene more precisely. Eventually we hope that these
recombinant DNA methods will be as successful for cerebellar ataxia as they have been already for Huntington disease.
When people call us about Huntington disease, we have to
say that the work is still experimental. We do not know that all
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of the mutations are alike, since some of the cases may result
from a mutation o n another chromosome. Even when that
question is resolved, the test will not help all families. In order
for the results to be informative, an affected person must be
heterozygous for the markers. Each affected individual has
one normal and one mutant gene, and each chromosome
must have a different marker. Furthermore, we have to have at
least two affected individuals in a family to be able to determine whether the mutant gene is on the chromosome
marked A or on the one marked B.
If you were at risk, wo uld you like to know early in life that
you do carry this gene? Should we offer this information to
other relatives who do not yet understand the problem? My
impression is that people generally would prefer to know, but
it is not simple. There are ethical issues in transmitting such
information and in understanding the effect on the life of
individuals. If you know in fact that you carry this gene, the
first time you drop something you may say, "Oh, no, it is
starting." Nonethel es, it wo uld be possible for you to avoid
reproduction and thus know that you are not transmitting the
gene to offspring.
A second illustration involves sickle cell anemia. The
underlying mutati on causes a change in the hemoglobin
molecule. The altered molecules form stiff rods that distort
the shape of the red blood cell. The liver and the spleen detect
these aberrant cells and remove the m from circulation. So
there are a number of other problems that result.
Adult hemogl obin has four parts, two alpha chains and two
beta. The alpha chains are made throughout development ;
the other half of the molecule changes from time to tim e. In
the embryo it is the epsilo n chain; then the gamma chain is
produced throughout most of fetal life. Toward th e end of
pregnancy that gene is turned off and the beta gene is turned
on. The sickle cell mutati on is in the beta gene and thus is not
expressed in the fetus.
It turns out that the genes are arranged along a chromosome in the same seq uence as they are expressed during
development. There is a reading system and at some point
one gene is turned off and the next gene is turned o n. So me
individuals have a small chromoso me segment missing at the
switch point and thus make fetal hemoglobin throughout life,
but the condition usually is not serious.
There has been some discussion about the individuals who
have sickle cell anemia. These people who have a mutant beta
gene might be better off if they had good fetal hemoglobin.
There are some chemicals that can be used to fool th e system
so that the reading frame will go back a step and produce fetal
hemoglobin. This would be a form of genetic engineering,
not by introducing something new, but by changing the
readout of the genes already there. The trouble is that some of
the chemicals used are potent carcinogens.
Martin Cline in California was working with mouse models
and became interested in beta zero thalassemia, another
hemoglobin disorder. He wanted to test the possibility that he
could introduce a normal gene into affected humans. He
requested permission in Californ ia, Italy and Israel. There was
a very long delay in Cal ifornia, and eventually a denial of the
request. Permission was granted in Italy and Israel. When he
carried out the procedure, however, he altered the protocol
slightly at the last minute. After a lo ng discussion he was
denied access to new federal funding for some time.
Shortly thereafter an article was published in the New England]ournal of Medicine(Table 2). The questi on was: When
can we say that we are ready to carry out gene therapy' The
conclusion was that for treating thalassemia, none of these
criteria had been met. So within the academic community
j ournal of the Minnesota Academy of Science

self-guiding rules of this sort have been developed.
Table 2. Criteria for gene therapy.
1. The new gene should be put into the target cells and remain
in them.
2. The new gene should be regulated appropriately.
3. The presence of the new gene should not harm the cell.

New England Journal of Medicine, Nov. 27, 1980

The third illustration is the growth hormone gene. There are
many different mutations that can lead to dwarfism. One
group involves short-limbed dwarfism, in which the trunk is
of normal length but the arms and legs are short. The other is
proportionate dwarfism, which can result from defective
growth hormone and other causes. What are the issues for this
second category? Under what circumstances is short stature a
defect rather than simply being the low end of a normal
distribution? Would it be appropriate to use growth hormone
in cases of dwarfism resulting from some other cause? Currently children who have slow development resulting from a
deficiency of growth hormone can be treated with growth
hormone derived from human cadavers, but this material is
very expensive and in short supply. Genetic engineering will
produce human growth hormone in larger quantity and presumably at lower cost. Furthermore, it is expected that safe
methods will be developed for the transfer of the gene itself,
thus avoiding the need for repeated injections.
These options will make treatment available to most of
those who have a diagnosed growth hormone defect, but
there may be the temptation to use the methods to "improve"
those who are otherwise normal. What if a father comes to a
doctor saying, "This new baby is wonderful, but I would like
him to be a basketball player." Is that medically appropriate?
There may well be serious disadvantages that come from
giving extra growth hormone. Does the doctor have a right to
refuse the request under those circumstances? As new techniques and new options become available, public expectations and pressures can play a large role in shaping the future.
Faced with these and other current questions, many feel
intuitively the need for restrictions on future developments.
One of the persons who has been most vocal concerning
genetic engineering is jeremy Rifkin. Injune 1983 he released
a resolution with the concluding statement shown in Table 3.
This would mean a complete embargo on a procedure, without regard to reasons for its use in a specific situation or
evidence for its safety. In my opinion, "limits" of this type
restrict discussion and tend to become outdated by later
research. My own preference is for the second type of statement, which is very cautious but nevertheless states some of
the criteria in making a decision.
One of Mr. Rifkin's supporting arguments is that once we
begin there is no place to stop (Table 4). That is known as the

slippery slope argument, but I do not agree. It is true that we
must be cautious. One thing may lead to another, but it is not
inevitable. What about the matter of perfection? As a biologist
I would argue that aiming at perfection is very different from
trying to alleviate specific identifiable disorders. Furthermore,
it is most unlikely that we would narrow the diversity. There is
such a large pool of diversity that intervention would have a
very small effect. Rifkin also brings in the eugenics argument
and invokes the thought of Hitler. Here he confuses the
distinction between a technology itself and the way in which
decisions are reached. If the new technology were used in an
authoritarian way by a government, we would all object
strongly. But that is a judgment on the means of control, not
on the technology itself.
Table 4. Some claims about genetic engineering.
Once we decide to begin the process of human genetic engineering, there is really no logical place to stop. If diabetes, sickle
cell anemia, and cancer are to be cured by altering the genetic
make-up of an individual, why not proceed to other "disorders":
myopia, color blindness, left handedness. Indeed what is to
preclude a society from deciding that a certain skin color is a
disorder?
What is the price we pay for embarking on a course whose final
goal is the "perfection" of the human species? ... It is very likely
that we will succeed in engineering our own extinction. Eliminating so called "bad genes" will lead to a dangerous narrowing of
the diversity in the gene pool.
In place of the shrill eugenic cries for racial purity, the new
commercial eugenics talks in pragmatic terms of medical
benefits and improvement in the quality of life. The old eugenics
was steeped in political ideology and motivated by fear and
hate. The new eugenics is grounded in medical advance and the
spectre of extending the human life span.
(J. Rifkin, 1984. Foundation on Economic Trends. Pp. 276-281
in: Levine, Carol (ed.) Taking Sides: Clashing Views on Controversial Bio-Ethical Issues. Guilford, CT: Dushkin Publishing
Group, Inc.)

My suggestions for the kinds of guidelines that we need are
shown in Table 5. Obviously the guidelines must make a
difference by dealing with important issues. They must be
understandable to the general public, but also present the
scientific data and issues fairly. Otherwise the people
involved in science and industry will pay no attention. They
must involve principles that transcend current science and
technology, and must recognize points of disagreement. If we
are going to have guidelines, we should attempt to meet these
criteria.
Table 5. Criteria for effective guidelines.
Effective Guidelines
1) Make a difference

Table 3. Two statements about genetic engineering.

2) Are understandable to the general public

Efforts to engineer specific genetic traits into the germli ne of the
human species should not be attempted. (J. Rifkin, 1984. Foundation on Economic Trends. Pp. 276-281 in: Levine, Carol (ed.)
Taking Sides: Clashing Views on Controversial Bio-Ethical
Issues. Guilford, CT: Dushkin Publishing Group, Inc.)

3) Present scientific data and issues fairly

The manipulation of genes in human germ or sex cells, if permitted at all, should be subject to special scrutiny, because not only
the individual, but also his or her descendants, may be affected.
(National Council of Churches of Christ/USA, 1984. Genetic
Engineering: Social and Ethical Consequences. New York: The
Pilgrim Press.)

What are the issues that should be addressed (Table 6)?
The need for caution in technical details is obvious. It is
important next to encourage reasonable expectations. There
may be a temptation for a corporation in its public relations to
make statements about a product that are misleading. We
should really tell the public what a product can and cannot be
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4) Reach beyond current science and technology
5) Recognize points of disagreement

11

Table 6. Guidelines for biotechnology.
1) Use caution

2) Encourage reasonable expectations
3) Avoid harm while doing good
4) Exercise stewardship
5) Respect human diversity
6) Protect individual freedoms
7) Foster community
8) Recognize the wholeness of human nature

expected to do. A third principle is to avoid harm but do good.
At the Boston conference one of the speakers argued that it is
worse to cause harm than to miss the opportunity to do good.
What do you think?
Stewardship is a term used in religious circles, but also in
conservation. It means that decisions are not self-centered but
are made in the spirit of answerability - answerable to others

now, and answerable to future generations. A person with
religious convictions would add answerable to God.
Fifth is respect for human diversity. There is a tendency to
talk about deformity or defect in a way that stigmatizes individ uals and treats them as less than human. It is important that
we protect individual freedom as much as possible.
We can foster community by emphasizing the significance
of the family, but a broader community may be involved in
many situations. With regard to the wholeness of human
nature, Ian Barbour at Carleton has said that we must view the
human both as a biological organism and as responsible self.
If we treat a disease without concern for the person, we've
missed something. When we talk abo ut the possibility of
"improving" humankind, we should explain carefully what
we mean. What are the essential points of human nature?
I conclude with a question found toward the end of the
President's Commission statement entitled Splicing Life: "By
what standards and toward what objectives should the great
new powers of genetic understanding be guided?"

Clearly, the issues surrounding biotechnology are as numerous as they are complex. Our technological achievements present us with th e ultimate qu estion: How can the capabilities of biotechnology be best used to benefit, not
harm, humanity? It is imperative that our society attempt to keep pace with our technical capabilities so that the power
of biotechnology will not be abused. This requires aUpersons, whether a representative of academia, industry, or the
lay public, to cooperate in establishing rational and realistic guidelines for the use of biotechnology. If we do not
establish a level of confidence and trust in the utilization of this technology, our "brave new world" of the future will
surely be a dark and dismal one.
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(continued fro m p. 3)
Acade my me mbers interested in becoming involved with these activities or
who want more information should contact The Minnesota Alliance for Science,
105 Experimental Engin eering, 208
Union Street S.E., University of Minnesota, Minneapolis, MN 55455.

•• * ••

Science News

The devel op mental processes of
higher organisms are the subject of much
current investigation. One of the key
questi ons asked by developmental bi ologists is how the genes that control
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development function. A recent advance
in this study was provided by Robert K.
Herman of the University of Mi nnesota.
Dr. Herman has taken advantage of the
biology of th e free-living nematode
worm Caenorhabditis elegansto provide
evidence for th e timing of certain genes
during development. C. elegans has a
developmental history characterized by a
fixed set of cell divisions yielding adult
worms with identical numb ers and
patterns of cells. Recent work has described all the cell divisions and provided
a complete cell lineage of every cell.
The chromosomes of this worm are
not structured li ke the chromosomes of
most other organisms. Instead of the
usual small centrom ere, a structure
necessary for proper division of the
chromosome, C. elegans has diffuse centromeres. These structures allow each
part of a chromosome to act as if it were a

whole chromosome at cell division. By
utilizing small fragments of normal
chromosomes Dr. Herman has been able
to "hide" recessive alleles of developmentally important genes in the normal
chromoso mes. As the worms age they
tend to lose these fragments and the
recessive alleles are expressed. By watch·
ing the timing of the loss and the expression of the recessive trait it has been
possible to show when in develo pment
certain genes are active.
The first genes examined in this way
determine a worm's response to chemi cal signals in th e environment. It now
seems that the genes controlling these
traits act very early in development. What
remains is to discover the exact mechanism of their expressio n.

•• * ••
Journal of the Min nesota Academy of Science

